Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands
- Hinsenveld, Florentien J
- Boormans, Joost L
- van der Poel, Henk G
- van der Schoot, Deric K E
- Vis, André N
- Aben, Katja K H
- Arends, T J
- Ausems, P J
- Baselmans, D
- Berger, Cpam
- Berrens, A
- Bickerstaffe, H
- Bos, S D
- Braam, M
- Buddingh, K T
- Claus, S
- Dekker, K
- van Doeveren, T
- Einerhand, Smh
- Fossion, Lmcl
- van Gennep, E J
- van Ginkel, N
- Palacios, LA Grondhuis
- Hermans, Tjn
- Hobijn, M M
- van Huystee, S H
- Jaspers-Valentijn, M
- Klaver, O S
- Koldewijn, E L
- Korsten, L
- Lenting, A
- Lentjes, K J
- Luiting, H B
- van der Meer, S
- Nieuwenhuijzen, J A
- Noordzij, M A
- Nooter, R I
- Notenboom, Caw
- Oomen, Rja
- van Roermund, Jgh
- de Rooij, J
- Roshani, H
- Schrier, B P
- van der Slot, M A
- Somford, D M
- Stelwagen, P J
- Stroux, Ama
- van der West, A
- Wijsman, B P
- Windt, Wakm
DOIAbstract
BACKGROUND: Radical cystectomy with pelvic lymph node dissection is the recommended treatment in non-metastatic muscle-invasive bladder cancer (MIBC). In randomised trials, robot-assisted radical cystectomy (RARC) showed non-inferior short-term oncological outcomes compared with open radical cystectomy (ORC). Data on intermediate and long-term oncological outcomes of RARC are limited.OBJECTIVE: To assess the intermediate-term overall survival (OS) and recurrence-free survival (RFS) of patients with MIBC and high-risk non-MIBC (NMIBC) who underwent ORC versus RARC in clinical practice.METHODS AND MATERIALS: A nationwide retrospective study in 19 Dutch hospitals including patients with MIBC and high-risk NMIBC treated by ORC (n = 1086) or RAR...
Add to ORKG